SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 130,611.89 |
| Enterprise Value ($M) | 150,095.89 |
| Book Value ($M) | 19,246.00 |
| Book Value / Share | 15.45 |
| Price / Book | 6.79 |
| NCAV ($M) | -21,749.00 |
| NCAV / Share | -17.46 |
| Price / NCAV | -6.01 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.01 |
| Return on Assets (ROA) | 0.01 |
| Return on Equity (ROE) | 0.03 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.20 |
| Current Ratio | 1.50 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18,000.00 |
| Assets | 58,995.00 |
| Liabilities | 39,749.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 28,754.00 |
| Operating Income | 10,869.00 |
| Net Income | 480.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 10,828.00 |
| Cash from Investing | -3,449.00 |
| Cash from Financing | -3,433.00 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 758,733 | 6,659,085 | 11.39 | |
| 1,587,626 | 5,664,293 | 28.03 | |
| 864,699 | 6,228,421 | 13.88 | |
| 927,716 | 5,123,878 | 18.11 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FGEN – FibroGen, Inc. | GBIO – Generation Bio Co. |
| GERN – Geron Corporation | GLUE – Monte Rosa Therapeutics, Inc. |
| GOSS – Gossamer Bio, Inc. |